transplant rejection
The company had previously planned to develop IVD kits for the US market but is now aiming to launch a lab-developed test in the second half of 2022.
CareDx to Study AlloSure Kidney for Routine Organ Transplant Surveillance in Pediatric Patients
The company is teaming up with the North American Pediatric Renal Trials and Collaborative Studies organization to study the long-term impact of AlloSure.
The company has signed a deal with Aarhus University that gives it access to a 40,000-sample biobank of patients who were screened for colorectal cancer.
The firm is aiming to create pan-organ transplant services that connect patients to doctors throughout the transplant and recovery process.
CareDx Patents Deemed Invalid in Court Battle Against Natera, Eurofins Viracor
In a separate case in which CareDx and Natera are suing each other for false advertising, a court has set a trial date in late October.
May 6, 2021
Natera Q1 Revenues Grow 62 Percent
May 5, 2021
CareDx Q1 Revenues up 76 Percent
Mar 19, 2021
Mar 16, 2021
NephroSant Raises $16M in Series A Funding Round
Feb 25, 2021
Feb 24, 2021
CareDx Q4 Revenues Up 64 Percent
Jan 27, 2021
Oct 29, 2020
CareDx Q3 Revenues Up 58 Percent
Oct 7, 2020